Zura Bio Limited filed a Form S-3 shelf registration statement with the SEC on October 27, 2026, covering up to $700,000,000 in aggregate offering price of Class A ordinary shares, preference shares, debt securities, warrants, and units, and including a sales agreement prospectus for up to $114,044,900 of Class A ordinary shares under an at-the-market facility with Leerink Partners LLC.

Key Highlights

  • Shelf size: The base prospectus covers securities with a maximum aggregate offering price of $700,000,000, according to the filing.
  • ATM tranche: A sales agreement prospectus covers up to $114,044,900 of Class A ordinary shares that may be sold through Leerink Partners LLC, and this amount is included within the $700,000,000 shelf total.
  • Sales Agreement amended: The original sales agreement with Leerink Partners LLC, dated September 3, 2024, was amended on October 27, 2026, the filing states.
  • Prior ATM sales: As of the date of the base prospectus, the company disclosed it had issued and sold Class A ordinary shares having an aggregate offering price of $10,955,100 under the Sales Agreement and a prior sales agreement prospectus.
  • Share price: On October 26, 2026, the last reported sales price of the Class A ordinary shares was $3.56 per share, according to the filing.
  • Company status: The registrant identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company.
  • Par value: Class A ordinary shares carry a par value of $0.0001 per share, as stated in the filing.

Zura Bio's $700 Million Shelf and $114 Million ATM Facility Details

Zura Bio Limited (NASDAQ:ZURA), a Cayman Islands-incorporated company with principal executive offices in Henderson, Nevada, filed a Form S-3 registration statement on October 27, 2026. The registration covers two prospectuses: a base prospectus permitting the offering of up to $700,000,000 in aggregate of Class A ordinary shares, preference shares, debt securities, warrants, and units, and a sales agreement prospectus for an at-the-market program with Leerink Partners LLC. The filing is subject to completion and may not be used to consummate a sale of securities until the registration statement becomes effective.

According to the filing, the company had already sold Class A ordinary shares totaling $10,955,100 in aggregate offering price under the Sales Agreement and a prior sales agreement prospectus. As a result, the remaining capacity available under the sales agreement prospectus is $114,044,900. The filing notes that if no Class A ordinary shares are sold under the Sales Agreement, the full $700,000,000 may be sold in other offerings pursuant to the base prospectus and a corresponding prospectus supplement. Conversely, upon termination of the Sales Agreement, any unsold portion of the $114,044,900 ATM tranche will be available for other offerings under the base prospectus.

The company disclosed that its Class A ordinary shares are listed on the Nasdaq Capital Market under the symbol "ZURA," with a last reported sales price of $3.56 per share on October 26, 2026. Securities offered under the base prospectus will be described in individual prospectus supplements, which will contain specific amounts, prices, and terms. Sandeep Kulkarni, Chief Executive Officer, is named as the agent for service of process. Cooley LLP is identified as outside counsel to the registrant.

What Was Disclosed

Zura Bio Limited filed an S-3 shelf registration statement on October 27, 2026, registering up to $700,000,000 in securities and including an at-the-market sales agreement prospectus for up to $114,044,900 of Class A ordinary shares through Leerink Partners LLC, with $10,955,100 already sold under prior arrangements.